COMMUNIQUÉS West-GlobeNewswire

SRx Health Solutions Hedges Investments in Cryptocurrency and Emerging Markets for Volatility Protection
18/03/2026
The Company will update shareholders in the near future on the proposed timing to close the EMJX transaction NORTH PALM BEACH, Fla., March 18, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) ( [...]
Engineered Silkworms Spin Spider Silk as Biotech Firm Targets Commercial Scale
18/03/2026
DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- www.247marketnews.com -- A biotechnology company developing genetically engineered silkworms says it’s moving toward commercial production of spider silk, a material long [...]
Lifeward Reports Fourth Quarter and Full Year 2025 Financial Results
18/03/2026
Advancing t ransformation into a d iversified b iomedical i nnovation c ompany with a c lear p ath to c ash f low p ositiv e Oramed s trategic t ransaction r eceives s hareholder a pproval ; Lifeward g ain s n ew o ral [...]
Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission
18/03/2026
Phyto-N 28-Day Repeat-Dose Study in Rats and Dogs Shows No Findings of Toxicological Significance at Maximum Feasible Dose, Enabling Advancement to GLP Toxicology Program Jericho, New York, March 18, 2026 (GLOBE [...]
Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline
18/03/2026
DUBLIN and BRIDGEWATER, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin”), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, applauded the [...]
Global survey reveals pet owners lack awareness of parasite risks and seek clearer prevention advice
18/03/2026
43% of pet owners report that their pets experienced parasite infections, with 75% looking for clearer parasite prevention advice. Veterinarians are seen as the most trusted source of pet health advice. “Small acts of [...]
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
18/03/2026
The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to initiate a Phase 2 trial in focal onset seizures [...]
Peace through well-being: Orion and CMI - Martti Ahtisaari Peace Foundation announce partnership
18/03/2026
ORION CORPORATION PRESS RELEASE 18 March 2026 at 10:00 EET Peace through well-being: Orion and CMI - Martti Ahtisaari Peace Foundation announce partnership Orion Corporation (“Orion Pharma”) and CMI - Martti Ahtisaari [...]
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements
18/03/2026
Portfolio receipts : • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties up 68% versus full [...]
Ovid Therapeutics Announces Pricing of $60 Million Private Placement
18/03/2026
Proceeds expected to support expansion of next-generation GABA-aminotransferase inhibitor, OV329, into tuberous sclerosis complex and infantile spasms Financing led by Point72 with participation from additional [...]
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
18/03/2026
- Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing [...]
Greenwich LifeSciences Provides Update on Upcoming AACR Meeting
18/03/2026
STAFFORD, Texas, March 18, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Valneva Reports Full Year 2025 Audited Consolidated Financial Results
18/03/2026
Total revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt [...]
BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025
18/03/2026
Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, March 18, 2026 (GLOBE NEWSWIRE) -- Significant clinical and regulatory progress across entire pipeline BV100: Initiated global registrational Phase 3 (RIV- [...]
Communiqué de presse : Le venglustat de Sanofi a reçu la désignation de thérapie innovante aux États-Unis pour la maladie de Gaucher de type 3
18/03/2026
Le venglusta t de Sanofi a reçu la désignation de thérapie innovante aux États-Unis pour la maladie de Gaucher de type 3 Paris, le 18 mars 2026 . La Food and Drug Administration (FDA) des États-Unis a accordé la [...]
UREVO Unveils CyberMega Across the DACH Region: The First Smart Treadmill Engineered for Marathon Training at Home
18/03/2026
BERLIN, March 18, 2026 (GLOBE NEWSWIRE) -- As marathon participation rises, runners increasingly require equipment that replicates the rigor and precision of road racing. To meet this demand, UREVO launched the [...]
Ipsen présente le potentiel transformateur de son pipeline d’immuno oncologie précoce au congrès AACR
18/03/2026
Les données précliniques d’IPN01203 seront dévoilées lors de la convoitée session « New Drugs on the Horizon », mettant en lumière le potentiel précoce de ce nouvel activateur de cellules T à transformer la prise en [...]
Valneva publie ses résultats financiers audités et consolidés pour l’exercice 2025
18/03/2026
Chiffre d’affaires de 174,7 millions d’euros, conforme aux prévisions, dont 157,9 millions de ventes de produits Solide position de trésorerie de 109,7 millions d’euros et flexibilité financière renforcée suite au [...]
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR
18/03/2026
IPN01203 data to be presented at coveted New Drugs on the Horizon program session, demonstrating early potential of this novel T cell activator to transform care in solid tumors ITGA2 revealed as novel target of Ipsen’s [...]

Pages